Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
partnerships
Biotech
AstraZeneca pens $5.3B pact with CSPC to develop oral drugs
AstraZeneca has returned to recent collaborator CSPC with $110 million in upfront cash to find new oral drugs for a range of chronic diseases.
James Waldron
Jun 13, 2025 5:56am
OSE to lead mRNA project with €1.3M from French government
May 21, 2025 4:26pm
Revised Blueprint-VantAI deal turns focus to molecular glues
May 20, 2025 10:32am
Tempest, amid cash drought, hunts for liver cancer drug partner
Apr 10, 2025 7:24am
Charles River and Valo pact nets preclinical lupus asset
Mar 26, 2025 6:30am
Opko, Entera share cost of 1st oral GLP-1/glucagon agonist study
Mar 17, 2025 10:10am
